Prolonged topotecan infusion with cisplatin in the first-line treatment of ovarian cancer: An NYGOG and ECOG study

Gynecologic Oncology

Volumn 100, Issue 2, 2006, Pages 324-329

  Hochster, Howard S ^a   Plimack, Elizabeth R ^a   Mandeli, John ^b   Wadler, Scott ^c   Runowicz, Carolyn ^d   Goldberg, Gary ^e   Speyer, James ^a   Wallach, Robert ^a   Muggia, Franco ^a  

^a NEW YORK UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^c NEW YORK PRESBYTERIAN HOSPITAL   (United States)

^d UNIVERSITY OF CONNECTICUT   (United States)

^e MONTEFIORE MEDICAL CENTER   (United States)

Author keywords

First line chemotherapy; Infusional chemotherapy; Ovarian cancer; Platinum; Topotecan

Indexed keywords

CISPLATIN; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ANOREXIA; ARTICLE; BLOOD TOXICITY; BONE MARROW SUPPRESSION; CANCER GROWTH; CANCER STAGING; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DEEP VEIN THROMBOSIS; DIARRHEA; DISEASE FREE SURVIVAL; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG TOLERANCE; FATIGUE; FEBRILE NEUTROPENIA; FEMALE; FEVER; FOLLOW UP; HUMAN; INFECTION; INFUSION SYSTEM; LUNG INFECTION; LYMPHOCYTOPENIA; MAJOR CLINICAL STUDY; MINIMAL RESIDUAL DISEASE; NAUSEA; NEUROPATHY; NEUTROPENIA; OVARY CANCER; PRIORITY JOURNAL; THROMBOCYTOPENIA; TOXICITY; TREATMENT OUTCOME; TREATMENT RESPONSE; VOMITING;

ADULT; AGED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CISPLATIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MIDDLE AGED; OVARIAN NEOPLASMS; TOPOTECAN;

EID: 30444457230     PISSN: 00908258     EISSN: 10956859     Source Type: Journal    
DOI: 10.1016/j.ygyno.2005.08.059     Document Type: Article

References (29)

1. A. Jemal, A. Thomas, T. Murray, and M. Thun Cancer statistics CA Cancer J. Clin. 52 2002 23 47
2. G.J. Creemers, G. Bolis, M. Gore, G. Scarfone, A.J. Lacave, and J.P. Guastalla Topotecan, an active drug in the second-line treatment of epithelial ovarian cancer: results of a large European phase II study J. Clin. Oncol. 14 1996 3056 3061
3. M.A. Bookman, H. Malmstrom, G. Bolis, A. Gordon, A. Lissoni, and J.B. Krebs Topotecan for the treatment of advanced epithelial ovarian cancer: an open-label phase II study in patients treated after prior chemotherapy that contained cisplatin or carboplatin and paclitaxel J. Clin. Oncol. 16 1998 3345 3352
4. W. ten Bokkel Huinink, M. Gore, J. Carmichael, A. Gordon, J. Malfetano, and I. Hudson Topotecan versus paclitaxel for the treatment of recurrent epithelial ovarian cancer J. Clin. Oncol. 15 1997 2183 2193
5. W.P. McGuire, J.A. Blessing, M.A. Bookman, S.S. Lentz, and C.J. Dunton Topotecan has substantial antitumor activity as first-line salvage therapy in platinum-sensitive epithelial ovarian carcinoma: a Gynecologic Oncology Group Study J. Clin. Oncol. 18 2000 1062 1067
6. S.H. Kaufmann, D. Peereboom, C.A. Buckwalter, P.A. Svingen, L.B. Grochow, and R.C. Donehower Cytotoxic effects of topotecan combined with various anticancer agents in human cancer cell lines J. Natl. Cancer Inst. 88 1996 734 741
7. E. Jonsson, H. Fridborg, K. Csoka, S. Dhar, C. Sundstrom, and P. Nygren Cytotoxic activity of topotecan in human tumour cell lines and primary cultures of human tumour cells from patients Br. J. Cancer 76 1997 211 219
8. S. Romanelli, P. Perego, G. Pratesi, N. Carenini, M. Tortoreto, and F. Zunino In vitro and in vivo interaction between cisplatin and topotecan in ovarian carcinoma systems Cancer Chemother. Pharmacol. 41 1998 385 390
9. H. Hochster, S. Wadler, C. Runowicz, L. Liebes, H. Cohen, and R. Wallach Activity and pharmacodynamics of 21-day topotecan infusion in patients with ovarian cancer previously treated with platinum-based chemotherapy. New York Gynecologic Oncology Group J. Clin. Oncol. 17 1999 2553 2561
10. H. Hochster, L. Liebes, J. Speyer, J. Sorich, B. Taubes, and R. Oratz Phase I trial of low-dose continuous topotecan infusion in patients with cancer: an active and well-tolerated regimen J. Clin. Oncol. 12 1994 553 559
11. R.C. Lilenbaum, A.A. Miller, G. Batist, S. Bernard, D.R. Hollis, and G.L. Rosner Phase I and pharmacologic study of continuous infusion topotecan in combination with cisplatin in patients with advanced cancer: a Cancer and Leukemia Group B study J. Clin. Oncol. 16 1998 3302 3309
12. ECOG Common Toxicity Criteria.
13. W.P. McGuire, W.J. Hoskins, M.F. Brady, P.R. Kucera, E.E. Partridge, and K.Y. Look Cyclophosphamide and cisplatin compared with paclitaxel and cisplatin in patients with stage III and stage IV ovarian cancer N. Engl. J. Med. 334 1996 1 6
14. M.J. Piccart, K. Bertelsen, K. James, J. Cassidy, C. Mangioni, and E. Simonsen Randomized intergroup trial of cisplatin-paclitaxel versus cisplatin-cyclophosphamide in women with advanced epithelial ovarian cancer: three-year results J. Natl. Cancer Inst. 92 2000 699 708
15. F.M. Muggia, P.S. Braly, M.F. Brady, G. Sutton, T.H. Niemann, and S.L. Lentz Phase III randomized study of cisplatin versus paclitaxel versus cisplatin and paclitaxel in patients with suboptimal stage III or IV ovarian cancer: a gynecologic oncology group study J. Clin. Oncol. 18 2000 106 115
16. R.F. Ozols, B.N. Bundy, B.E. Greer, J.M. Fowler, D. Clarke-Pearson, and R.A. Burger Phase III trial of carboplatin and paclitaxel compared with cisplatin and paclitaxel in patients with optimally resected stage III ovarian cancer: a Gynecologic Oncology Group study J. Clin. Oncol. 21 2003 3194 3200
17. A. duBois, H.J. Luck, W. Meier, H.P. Adams, V. Mobus, and S. Costa A randomized clinical trial of cisplatin/paclitaxel versus carboplatin/paclitaxel as first-line treatment of ovarian cancer J. Natl. Cancer Inst. 95 2003 1320 1329 [Notes: CORPORATE NAME: Arbeitsgemeinschaft Gynakologische Onkologie Ovarian Cancer Study Group]
18. P.A. Vasey, G.C. Jayson, A. Gordon, H. Gabra, R. Coleman, and R. Atkinson Phase III randomized trial of docetaxel-carboplatin versus paclitaxel- carboplatin as first-line chemotherapy for ovarian carcinoma J. Natl. Cancer Inst. 96 22 2004 1682 1691 [United States]
19. M. Nogue, L. Cirera, A. Arcusa, E. Batiste-Alentorn, A. Balil, and A. Font Tusquets I: Phase II study of gemcitabine and cisplatin in chemonaive patients with advanced epithelial ovarian cancer Anti-cancer Drugs 13 2002 839 845
20. A. Romanini, L. Tanganelli, F. Carnino, A. Fanucchi, R. Lionetto, and S. Pastorino First-line chemotherapy with epidoxorubicin, paclitaxel, and carboplatin for the treatment of advanced epithelial ovarian cancer patients Gynecol. Oncol. 89 2003 354 359
21. T. Sugiyama, M. Yakushiji, T. Kamura, M. Ikeda, N. Umesaki, and K. Hasegawa Irinotecan (CPT-11) and cisplatin as first-line chemotherapy for advanced ovarian cancer Oncology 63 2002 16 22 [Notes: CORPORATE NAME: Japan CPT-11 Study Group]
22. H.A. Burris III, A.R. Hanauske, R.K. Johnson, M.H. Marshall, J.G. Kuhn, and S.G. Hilsenbeck Activity of topotecan, a new topoisomerase I inhibitor, against human tumor colony-forming units in vitro J. Natl. Cancer Inst. 84 1992 1816 1820
23. S.A. Ghamande, and M.S. Piver Role of salvage chemotherapy with topotecan and cisplatin in patients with paclitaxel- and platinum-resistant recurrent ovarian or primary peritoneal cancer: a phase II pilot study J. Surg. Oncol. 72 1999 162 166
24. A. Ardizzoni, C. Manegold, C. Debruyne, R. Gaafar, E. Buchholz, and E.F. Smit European organization for research and treatment of cancer (EORTC) 08957 phase II study of topotecan in combination with cisplatin as second-line treatment of refractory and sensitive small cell lung cancer Clin. Cancer Res. 9 2003 143 150 [Notes: CORPORATE NAME: Giuseppe giaccone European organization for research and treatment of cancer (EORTC) lung cancer groups]
25. L.J. Copeland, M. Bookman, and E. Trimble Clinical trials of newer regimens for treating ovarian cancer: the rationale for Gynecologic Oncology Group Protocol GOG 182-ICON5 Gynecol. Oncol. 90 2003 S1 S7 [Notes: CORPORATE NAME: Gynecologic Oncology Group Protocol GOG 182-ICON5]
26. P. Hoskins, E. Eisenhauer, I. Vergote, J. Dubuc-Lissoir, B. Fisher, and R. Grimshaw Phase II feasibility study of sequential couplets of cisplatin/topotecan followed by paclitaxel/cisplatin as primary treatment for advanced epithelial ovarian cancer: a National Cancer Institute of Canada Clinical Trials Group Study J. Clin. Oncol. 18 2000 4038 4044
27. J.M. Lu, H. Hochster, J. Sorich, A. Francois, J. Escalon, and P. Ivy Phase I study of oxaliplatin and topotecan infusion in patients with previously treated ovarian cancer Proc. Am. Soc. Clin. Oncol. 22 2003 463 [abstr 1860]
28. D.M. O'Malley, M. Azodi, A. Makkenchery, J. Tangir, J. McAlpine, and M. Kelly Weekly topotecan in heavily pretreated patients with recurrent epithelial ovarian cancer Gyencol. Oncol. 98 2 2005 242 248
29. T. Levy, M. Inbar, J. Menczer, D. Grisaru, M. Glezerman, and T. Safra Phase II study of weekly topotecan in patients with recurrent or persistent epithelial ovarian cancer Gynecol. Oncol. 95 3 2004 686 690